Ivor Percent

2.8k total citations · 1 hit paper
33 papers, 715 citations indexed

About

Ivor Percent is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Ivor Percent has authored 33 papers receiving a total of 715 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Ivor Percent's work include Cancer Immunotherapy and Biomarkers (12 papers), Cancer Genomics and Diagnostics (8 papers) and Renal cell carcinoma treatment (7 papers). Ivor Percent is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Cancer Genomics and Diagnostics (8 papers) and Renal cell carcinoma treatment (7 papers). Ivor Percent collaborates with scholars based in United States, United Kingdom and Germany. Ivor Percent's co-authors include Arash Rezazadeh Kalebasty, Andres Forero‐Torres, James Posey, Slawomir Wojtowicz‐Praga, Tina E. Wood, Mansoor N. Saleh, Jatin J. Shah, Catherine Copigneaux, Feng Luo and Thomas E. Hutson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Ivor Percent

33 papers receiving 699 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

2022 125 citations Xīn Gào, Howard A. Burris et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ivor Percent United States	13	412	371	299	155	78	33	715
Marie‐Paule Sablin France	18	499 1.2×	410 1.1×	289 1.0×	354 2.3×	64 0.8×	50	942
Ken Uchibori Japan	15	567 1.4×	360 1.0×	614 2.1×	156 1.0×	36 0.5×	59	885
Shinnosuke Ikemura Japan	18	485 1.2×	494 1.3×	487 1.6×	233 1.5×	44 0.6×	46	959
Karen A. Cadoo United States	19	365 0.9×	241 0.6×	211 0.7×	162 1.0×	60 0.8×	74	868
Jih‐Hsiang Lee Taiwan	19	669 1.6×	347 0.9×	561 1.9×	196 1.3×	98 1.3×	37	1.0k
Hirva Mamdani United States	19	597 1.4×	364 1.0×	436 1.5×	131 0.8×	115 1.5×	102	1.0k
Hideki Terai Japan	15	297 0.7×	480 1.3×	358 1.2×	199 1.3×	28 0.4×	41	778
Aimee Bence Lin United States	18	636 1.5×	622 1.7×	259 0.9×	144 0.9×	31 0.4×	42	977
Alessandra Capodanno Italy	14	574 1.4×	323 0.9×	375 1.3×	179 1.2×	49 0.6×	17	872
Christopher Gresty United Kingdom	10	700 1.7×	343 0.9×	441 1.5×	165 1.1×	23 0.3×	22	914

Countries citing papers authored by Ivor Percent

Since Specialization

Citations

This map shows the geographic impact of Ivor Percent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivor Percent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivor Percent more than expected).

Fields of papers citing papers by Ivor Percent

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivor Percent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivor Percent. The network helps show where Ivor Percent may publish in the future.

Co-authorship network of co-authors of Ivor Percent

This figure shows the co-authorship network connecting the top 25 collaborators of Ivor Percent. A scholar is included among the top collaborators of Ivor Percent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivor Percent. Ivor Percent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mahalingam, Devalingam, Rachna T. Shroff, Benedito A. Carneiro, et al.. (2025). Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).. Journal of Clinical Oncology. 43(16_suppl). 4006–4006. 2 indexed citations

Paz‐Ares, Luis, Shobhit Baijal, Pilar Garrido, et al.. (2024). 1314P Patient-reported outcomes (PROs) from the phase III EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel (doc) in metastatic non-small cell lung cancer (mNSCLC). Annals of Oncology. 35. S836–S838. 1 indexed citations

Hong, David S., Federico Cappuzzo, Byoung Chul Cho, et al.. (2024). Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations. Lung Cancer. 190. 107512–107512. 6 indexed citations

Borghaei, Hossein, Melissa L. Johnson, Edward B. Garon, et al.. (2023). LBA63 SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC). Annals of Oncology. 34. S1308–S1308. 4 indexed citations

Petrylak, Daniel P., Benjamin Garmezy, John Shen, et al.. (2023). 1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations. Annals of Oncology. 34. S973–S974. 4 indexed citations

Sweeney, Christopher J., Ivor Percent, Sunil Babu, et al.. (2022). Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 28(11). 2237–2247. 31 indexed citations

Gào, Xīn, Howard A. Burris, Jacqueline Vuky, et al.. (2022). Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 40(6_suppl). 17–17. 125 indexed citations breakdown →

Hussein, Maen, Johanna C. Bendell, Hendrik‐Tobias Arkenau, et al.. (2021). Platform trial of BI 754091, an anti-PD-1 antibody, in patients with previously treated advanced solid tumors: Combination with BI 836880, a VEGF/Ang2-blocking nanobody.. Journal of Clinical Oncology. 39(3_suppl). TPS152–TPS152. 2 indexed citations

Tykodi, Scott S., Lucio Gordan, Robert Alter, et al.. (2021). Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.. Journal of Clinical Oncology. 39(6_suppl). 309–309. 13 indexed citations

10.

Emamekhoo, Hamid, Mark R. Olsen, Bradley Curtis Carthon, et al.. (2021). Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.. Journal of Clinical Oncology. 39(15_suppl). 4515–4515. 5 indexed citations

11.

McCune, Steve, Leora Horn, Ivor Percent, et al.. (2019). EP1.12-06 New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting. Journal of Thoracic Oncology. 14(10). S1018–S1019. 1 indexed citations

12.

Owonikoko, Taofeek K., Ramaswamy Govindan, Neal Ready, et al.. (2019). Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. Annals of Oncology. 30. ii77–ii77. 66 indexed citations

13.

Shapiro, Jeremy, Ray McDermott, Josep M. Piulats, et al.. (2019). Abstract 727: Comprehensive genomic profiling of >1000 plasma and tumor tissue samples from metastatic castration-resistant prostate cancer (mCRPC) patients gives insight into targeted treatment strategies. Cancer Research. 79(13_Supplement). 727–727. 1 indexed citations

14.

Abida, Wassim, Alan H. Bryce, Nicholas J. Vogelzang, et al.. (2019). Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2.. Journal of Clinical Oncology. 37(15_suppl). 5031–5031. 4 indexed citations

15.

Emamekhoo, Hamid, Mark R. Olsen, Bradley Curtis Carthon, et al.. (2019). Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.. Journal of Clinical Oncology. 37(15_suppl). 4517–4517. 27 indexed citations

16.

Abida, Wassim, Alan H. Bryce, Nicholas J. Vogelzang, et al.. (2018). Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. Annals of Oncology. 29. viii272–viii272. 40 indexed citations

17.

Petrylak, Daniel P., K.N. Chi, Alexandra Drakaki, et al.. (2017). RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma. Annals of Oncology. 28. v621–v621. 4 indexed citations

18.

Forero‐Torres, Andres, Jatin J. Shah, Tina E. Wood, et al.. (2010). Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5). Cancer Biotherapy and Radiopharmaceuticals. 25(1). 13–19. 116 indexed citations

19.

Forero‐Torres, Andres, Mansoor N. Saleh, J. Galleshaw, et al.. (2010). Pilot Trial of Preoperative (Neoadjuvant) Letrozole in Combination With Bevacizumab in Postmenopausal Women With Newly Diagnosed Estrogen Receptor— or Progesterone Receptor—Positive Breast Cancer. Clinical Breast Cancer. 10(4). 275–280. 29 indexed citations

20.

Forero‐Torres, Andres, Sui Shen, Hazel B. Breitz, et al.. (2005). Pretargeted Radioimmunotherapy (RIT) with a Novel Anti-TAG-72 Fusion Protein. Cancer Biotherapy and Radiopharmaceuticals. 20(4). 379–390. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact